Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))

Loic Verlingue; David Malka; Adrien Allorant; Christophe Massard; Charles Ferté; Ludovic Lacroix; Etienne Rouleau; Nathalie Auger; Maud Ngo; Claudio Nicotra; Thierry De Baere; Lambros Tselikas; Bakar Ba; Stefan Michiels; Jean Yves Scoazec; Valérie Boige; Michel Ducreux; Jean Charles Soria; Antoine Hollebecque

doi:10.1016/j.ejca.2018.01.077

Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))

Loic Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Etienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra, Thierry De Baere, Lambros Tselikas, Bakar Ba, Stefan Michiels, Jean Yves Scoazec, Valérie Boige, Michel Ducreux, Jean Charles Soria, Antoine Hollebecque

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

The authors regret that figure 2 in the original article appears incorrect. The correct figure 2 and caption are included below. The authors would like to apologise for any inconvenience caused. [Figure presented] Fig 2. Description of the molecular alterations found in the cohort of all advanced biliary tract cancers (aBTC) patients included in the MOSCATO-01 trial, colored by type of alteration.

Original language	English
Pages (from-to)	156-157
Number of pages	2
Journal	European Journal of Cancer
Volume	93
DOIs	https://doi.org/10.1016/j.ejca.2018.01.077
Publication status	Published - 1 Apr 2018

Access to Document

10.1016/j.ejca.2018.01.077

Cite this

Verlingue, L., Malka, D., Allorant, A., Massard, C., Ferté, C., Lacroix, L., Rouleau, E., Auger, N., Ngo, M., Nicotra, C., De Baere, T., Tselikas, L., Ba, B., Michiels, S., Scoazec, J. Y., Boige, V., Ducreux, M., Soria, J. C., & Hollebecque, A. (2018). Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013)). European Journal of Cancer, 93, 156-157. https://doi.org/10.1016/j.ejca.2018.01.077

@article{f837c491a97748c285555503cb8b7e00,

title = "Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))",

abstract = "The authors regret that figure 2 in the original article appears incorrect. The correct figure 2 and caption are included below. The authors would like to apologise for any inconvenience caused. [Figure presented] Fig 2. Description of the molecular alterations found in the cohort of all advanced biliary tract cancers (aBTC) patients included in the MOSCATO-01 trial, colored by type of alteration.",

author = "Loic Verlingue and David Malka and Adrien Allorant and Christophe Massard and Charles Fert{\'e} and Ludovic Lacroix and Etienne Rouleau and Nathalie Auger and Maud Ngo and Claudio Nicotra and {De Baere}, Thierry and Lambros Tselikas and Bakar Ba and Stefan Michiels and Scoazec, {Jean Yves} and Val{\'e}rie Boige and Michel Ducreux and Soria, {Jean Charles} and Antoine Hollebecque",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.ejca.2018.01.077",

language = "English",

volume = "93",

pages = "156--157",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Verlingue, L, Malka, D, Allorant, A, Massard, C, Ferté, C, Lacroix, L, Rouleau, E, Auger, N, Ngo, M, Nicotra, C, De Baere, T, Tselikas, L, Ba, B, Michiels, S, Scoazec, JY, Boige, V, Ducreux, M, Soria, JC & Hollebecque, A 2018, 'Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))', European Journal of Cancer, vol. 93, pp. 156-157. https://doi.org/10.1016/j.ejca.2018.01.077

Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013)). / Verlingue, Loic; Malka, David; Allorant, Adrien et al.
In: European Journal of Cancer, Vol. 93, 01.04.2018, p. 156-157.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Precision medicine for patients with advanced biliary tract cancers

T2 - An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))

AU - Verlingue, Loic

AU - Malka, David

AU - Allorant, Adrien

AU - Massard, Christophe

AU - Ferté, Charles

AU - Lacroix, Ludovic

AU - Rouleau, Etienne

AU - Auger, Nathalie

AU - Ngo, Maud

AU - Nicotra, Claudio

AU - De Baere, Thierry

AU - Tselikas, Lambros

AU - Ba, Bakar

AU - Michiels, Stefan

AU - Scoazec, Jean Yves

AU - Boige, Valérie

AU - Ducreux, Michel

AU - Soria, Jean Charles

AU - Hollebecque, Antoine

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The authors regret that figure 2 in the original article appears incorrect. The correct figure 2 and caption are included below. The authors would like to apologise for any inconvenience caused. [Figure presented] Fig 2. Description of the molecular alterations found in the cohort of all advanced biliary tract cancers (aBTC) patients included in the MOSCATO-01 trial, colored by type of alteration.

AB - The authors regret that figure 2 in the original article appears incorrect. The correct figure 2 and caption are included below. The authors would like to apologise for any inconvenience caused. [Figure presented] Fig 2. Description of the molecular alterations found in the cohort of all advanced biliary tract cancers (aBTC) patients included in the MOSCATO-01 trial, colored by type of alteration.

UR - http://www.scopus.com/inward/record.url?scp=85041920715&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.01.077

DO - 10.1016/j.ejca.2018.01.077

M3 - Comment/debate

C2 - 29454743

AN - SCOPUS:85041920715

SN - 0959-8049

VL - 93

SP - 156

EP - 157

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L et al. Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013)). European Journal of Cancer. 2018 Apr 1;93:156-157. doi: 10.1016/j.ejca.2018.01.077

Corrigendum to “Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial” [Eur J Cancer 87 (2017) 122–130] (S0959804917313539) (10.1016/j.ejca.2017.10.013))

Abstract

Access to Document

Other files and links

Cite this